Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: Patient recruitment for th…
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: Patient recruitment for th…
Proteo, Inc. (OTCQB: PTEO; Freiverkehr Frankfurt: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announc…
Proteo, Inc. (OTCQB: PTEO; Freiverkehr Frankfurt: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announc…
Proteo, Inc. (OTCQB: PTEO; Freiverkehr Frankfurt: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announc…
Die Proteo, Inc. (OTCQB: PTEO; Freiverkehr Frankfurt: WKN: 925981) und ihre 100-prozentige Tochtergesellschaft Proteo Bi…